Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
This week an international team of astronomers reports the first multiple-star system to be observed during the earliest stage of formation. This finding supports model predictions about how two- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results